Moyom Aphranel CaHA Filler EU MDR
Analysis based on 6 articles · First reported May 28, 2026 · Last updated May 28, 2026
The EU MDR certification for Aphranel® MagiCCrystal CaHA Filler by Sana Biotechnology is expected to positively impact Sana Biotechnology's market share and revenue by opening up the European Union market. This also signals a growing trend of Asian-Pacific companies successfully navigating stringent international regulatory frameworks, potentially increasing competition in the global medical aesthetics industry.
Sana Biotechnology announced that its premium regenerative aesthetics product, Aphranel® MagiCCrystal CaHA Filler, officially achieved European Union Medical Device Regulation (EU MDR) certification on May 18, 2026. This certification, obtained after a rigorous 2-year and 7-month process under the MDR Class III pathway, allows the product to be sold in the European Union market. Aphranel® MagiCCrystal CaHA Filler is among the first regenerative CaHA injectable fillers from the Asia-Pacific region to receive direct EU MDR certification. The certification confirms compliance with the European Union's strict regulatory requirements for quality management, clinical evaluation, manufacturing standards, safety, traceability, and post-market surveillance. BSI Group, a UK-based Notified Body, assisted Sana Biotechnology in the conformity assessment. This achievement is a significant step in Sana Biotechnology's long-term international strategy to establish a global regenerative aesthetics brand originating from China.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard